Dr Török qualified in Medicine from the Universities of Oxford and London. She completed her postgraduate medical training in Oxford and then spent a year as a Clinical Research Fellow in the Department of Medicine, Imperial College doing hepatitis C research. She received her specialist training in Infectious Diseases and Medical Microbiology in Oxford. From 2004 to 2008 she was a Wellcome Research Training Fellow at the Oxford University Clinical Research Unit in Vietnam, where she did her PhD research in HIV and tuberculosis.
In 2009 Dr Török was appointed as a Consultant in Infectious Diseases at Addenbrooke’s Hospital, Cambridge and set up two new clinical services – a bacteraemia consult service and an outpatient parenteral antibiotic therapy (OPAT) service.
In 2011 she joined Professor Peacock’s research group at University of Cambridge as a Senior Research Associate and Honorary Consultant in Infectious Diseases and Medical Microbiology. In 2014 she was awarded a Clinician Scientist Fellowship by the Academy of Medical Sciences and the Health Foundation.
Dr Török’s current research focuses on translating microbial genomics from a research tool into clinical practice to improve the diagnosis of infectious diseases, infection control and public health. She has extensive clinical research experience in infectious diseases in the UK and in south-east Asia, and is involved in national and international studies of Staphylococcus aureus bacteraemia. She also has interests in medical education and public engagement.
Saunderson RB, Gouliouris T, Nickerson EK, Cartwright EJ, Kidney A, Aliyu SH, Brown NM, Limmathurotsakul D, Peacock SJ, Török ME. Impact of routine bedside infectious diseases consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adults. Clin Microbiol Infect. 2015 (in press).
Ellington MJ, Reuter S, Harris SR, Holden MT, Cartwright EJ, Greaves D, Gerver SM, Hope R, Brown NM, Török ME, Parkhill J, Köser CU, Peacock SJ. Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2015 Feb 19. pii: S0924-8579(15)00064-3. doi: 10.1016/j.ijantimicag.2015.01.009. [Epub ahead of print]
Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME .Elucidation of drug-resistance mechanisms is crucial for development of new anti-tuberculosis agents. Lancet. 2015 Jan 24;385(9965):305-7.
Davies A, Scott S, Badger B, Török ME, Peacock SJ. Public perceptions of bacterial whole-genome sequencing for tuberculosis. Trends Genet. 2015 Feb;31(2):58-60.
Török ME. Tuberculous meningitis – advances in diagnosis and treatment . Br Med Bull. 2015 Feb 18. pii: ldv003. [Epub ahead of print]